Pfizer Biopharma JV To Go Public In $780M SPAC Union

Law360 (July 30, 2020, 6:46 PM EDT) -- Cerevel Therapeutics Inc., a Pfizer joint venture focusing on neurological diseases, said Thursday that it was being taken public by a blank check company backed by Perceptive Advisors in a $780 million merger advised on by Kirkland, Goodwin and Ropes & Gray.

As part of the deal to combine Cerevel and Arya Sciences Acquisition Corp. II, led by Kirkland & Ellis LLP, Arya would become a Delaware corporation, rename itself Cerevel Therapeutics Holdings Inc. and relist its stock on Nasdaq under the ticker symbol CERE, according to a statement.

The agreement follows the blank check company raising $130 million in a...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!